a modern approach to ending cancer mortality.
% of Patients w/ctDNA Treatment Remain Relapse Free
Our mission is to leverage biological signalling via molecular-based diagnostics & therapeutics to tackle cancer mortality.
Cell-free DNA represents the key to unlocking tumour heterogeneity
Our physicians utilize NGS to determine the presence of cancer cells.
MCED testing costs decreased by >90%
This positive growth directs consumers to more affordable and reliable testing solutions (i.e. $500 reimbursement price).
Liquid Biopsy>Tissue Biopsy
By implementing liquid biopsy patients are less likely to endure the risk of disease progression through this screening-based technique.
minimally invasive diagnostics
sequencing alone is not enough.
Just sequencing ctDNA mutations alone does not provide an adequate foundation to detect early-onset cancers.
To ensure the viability of cancer screening, combining low-dose CT scanning can directly increase diagnosis detection.
meet the brain behind oncolnyx
CEO & Founder of Oncolnyx
Lauren Pearson is an incoming pre-medical student passionate about healthcare innovation. Her current focus is on molecular diagnostics and primary prevention methodology for patients at risk for cancer.